CLINICAL_TRIALS
research
· 2025-09-19
Clinical Trial Update: Study of CM313 in Subject With IgA Nephropathy [Phase 2]
Summary
A Phase 2 clinical trial evaluating CM313 for IgA nephropathy by Keymed Biosciences, currently not yet recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Keymed Biosciences Co.Ltd | Conditions: IgA Nephropathy | Phase 2 | Status: NOT_YET_RECRUITING